Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURF trial
2025-523898-42-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of indocyanine green in Non-hematologic malignancy, head and neck cancer (HNC), gastrointestinal cancer and 4 more, sponsored by Erasmus MC. Planned start Jan 2026; status: authorised.
02
Drugs
indocyanine green
03
Conditions
Non-hematologic malignancyhead and neck cancer (HNC)gastrointestinal cancerhepatobiliary cancer (HBC)breast cancer
Beyond the preview
Go deeper on 2025-523898-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523898-42-00.